ProfileGDS5678 / 1442333_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 51% 51% 51% 50% 51% 50% 52% 50% 50% 51% 51% 50% 51% 51% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.278651
GSM967853U87-EV human glioblastoma xenograft - Control 23.2301951
GSM967854U87-EV human glioblastoma xenograft - Control 33.2305451
GSM967855U87-EV human glioblastoma xenograft - Control 43.1386150
GSM967856U87-EV human glioblastoma xenograft - Control 53.1783551
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.2982450
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.3367752
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.206950
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.1872450
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.2142451
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.2150151
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.1477950
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.2251851
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.2207251